Supernus Pharmaceuticals
SUPN
107 hedge funds and large institutions have $309M invested in Supernus Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 11 closing their positions.
136% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 11
85% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $1.19M
50% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 26
15% more funds holding
Funds holding: 93 → 107 (+14)
0% less capital invested
Capital invested by funds: $309M → $309M (-$952K)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIS
AlphaOne Investment Services
West Chester,
Pennsylvania
|
+$3.96M |
| 2 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$3.52M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.94M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$2.66M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$2.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OHCM
Orchard Hill Capital Management
New York
|
-$9.95M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.86M |
| 3 |
JG
Jefferies Group
New York
|
-$4.42M |
| 4 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$1.36M |
| 5 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$1.29M |
SUPN Hedge Fund Activity: Q4 2014 in Review
107 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2014, worth a combined $309M — down 0.31% from $309M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SUPN positions and 11 closed out — a net gain of 15 holders — while 39 added to existing stakes and 26 trimmed.
The largest buyer was AlphaOne Investment Services, opening a new position worth an estimated $3.96M. The largest seller was Orchard Hill Capital Management, exiting entirely with an estimated $9.95M sold.
- 107 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2014, up from 93 in Q3 2014.
- Funds reported $309M of Supernus Pharmaceuticals stock for Q4 2014, down 0.31% quarter-over-quarter.
- 26 funds opened new Supernus Pharmaceuticals positions in Q4 2014 and 11 closed out, a net change of +15 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2014 was AlphaOne Investment Services, an estimated $3.96M added.
- The largest Supernus Pharmaceuticals seller in Q4 2014 was Orchard Hill Capital Management, an estimated $9.95M sold.
Based on aggregated 13F filings for Q4 2014.